Kyōwa Hakkō Kirin (4151) Stock Price, Fundamentals & Analysis

What 4151 does

Kyōwa Hakkō Kirin (4151) is a Japan-based healthcare company listed on the Tokyo Stock Exchange that researches, develops, manufactures, and markets pharmaceuticals in Japan, the Americas, Europe, and Asia. Its portfolio includes Ziftomenib, an oral menin inhibitor for adult relapsed or refractory acute myeloid leukemia with a nucleophosmin 1 mutation, and Lumicef for palmoplantar pustulosis. The company also has several clinical-stage assets, including KHK4083/AMG 451 rocatinlimab in Phase III for atopic dermatitis and prurigo nodularis, KK8398 infigratinib in Phase III for achondroplasia, OTL-203 in Phase III for Hurler syndrome, KHK4951 tivozanib in Phase II for diabetic macular edema and neovascular age-related macular degeneration, and OTL-201 in Phase II for Sanfilippo syndrome type A. 4151 is part of the Tokyo Stock Exchange stocks universe and sits in the Drug Manufacturers - Specialty & Generic industry, alongside peers such as Sumitomo Dainippon Pharma (4506), Terumo (4543), Astellas (4503), M3, Inc. (2413), Chugai Pharmaceutical (4519), Takeda Pharmaceutical (4502), and Shionogi (4507).

Key numbers explained

• Price: 2,267 JPY is the latest trading price of a single share of Kyōwa Hakkō Kirin (4151) on the Tokyo Stock Exchange.
• P/E ratio: the trailing P/E ratio of 14.6 shows how much investors pay per yen of the company's last 12 months of earnings; the forward P/E ratio of 16.3 uses expected future earnings instead.
• Dividend yield: the dividend yield of 3.09% tells you the annual dividend payment as a percentage of the current share price, based on the exDividendDate of 29 Dec 2026 and a 43% share of earnings paid out as dividends.
• Beta: a beta of 0.14 suggests the stock's price tends to move much less than the broader market, indicating lower sensitivity to market swings.
• Market cap: 1.19T JPY reflects the total market value of all outstanding shares, while employees: 5,173 gives a sense of the company's scale.
• Revenue, trailing 12 months: 529.8B JPY with revenue growth, year over year: 15.3% shows top-line expansion; profitMargin: 15.4% and operatingMargin: 10% describe how much of that revenue turns into profit and operating income.
• Return on equity: 9.3% measures how effectively the company generates profit from shareholders' equity, and priceToBook: 1.3 compares the share price to the company's book value per share.
• Lowest and highest price in the last 52 weeks: 2,109 – 2,912 JPY shows the recent trading range, while price change over the last 52 weeks: -0.6% indicates a slight decline from one year ago to today.

What to watch

Investors tracking Kyōwa Hakkō Kirin (4151) often watch its clinical pipeline, since late-stage drug candidates can influence long-term growth expectations. The nextEarningsDate of 2 Nov 2026 is a natural point to review updated guidance and pipeline progress. Because 4151 operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, regulatory decisions, pricing policies, and patent timelines can affect its results. The relatively low beta of 0.14 means the share may be less volatile than the broader market, which can appeal to risk-conscious investors. As a component of the Nikkei 225, 4151 can also be influenced by broad Japanese equity flows and investor sentiment toward the healthcare segment.